Vertex to share new data at European Hematology Association (EHA) Congress
Vertex and CRISPR Therapeutics to present on investigational gene-editing therapy for severe hemoglobinopathies
View our 2020 Corporate Responsibility Report
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2020.
Type 1 Diabetes Cell Therapy Program Receives Fast Track Designation and Initiates Phase 1/2 Clinical Trial
We announced that the U.S. FDA granted us Fast Track Designation and that we’ve opened our Phase 1/2 clinical trial for our investigational cell therapy for the treatment of type 1 diabetes.
U.S. FDA Approves Label Expansions for Three of Our Cystic Fibrosis Medicines
Featured contents
We Are Vertex